Petros Pharmaceuticals

What Petros Pharmaceuticals does

Petros Pharmaceuticals is a publicly traded (formerly Nasdaq: PTPI), New Jersey-domiciled specialty pharmaceutical company focused on men's health. The company was formed in December 2020 through the merger of Metuchen Pharmaceuticals, LLC and Neurotrope, Inc., and has subsequently repositioned around a single strategic thesis: developing Rx-to-OTC switch programs to convert prescription pharmaceuticals, principally erectile dysfunction treatments and complementary vacuum therapy devices, into over-the-counter alternatives. The intended outcome of these programs is to expand consumer access to established active ingredients by removing the physician-prescription gate and reaching patients through standard pharmaceutical wholesale and pharmacy retail channels.

The product portfolio is narrow and pipeline-driven. Core named assets include prescription and OTC-eligible erectile dysfunction treatment products, vacuum therapy devices, and a development pipeline explicitly framed as an Rx-to-OTC switch platform. No patents, trademarks, or proprietary scientific assets are disclosed in the input data. The core technology is regulatory and clinical in nature — execution of FDA switch studies and labeling — rather than a novel chemical or biological platform. Operations are US-only, with offices in Freehold, NJ (headquarters per the privacy policy) and Cranford, NJ. The company is small (11-50 employees), reliant on a lean leadership team that combines interim CFO Robert Weinstein, President/CCO Fady Boctor (20+ years pharma commercial experience at Novartis, Forest, Auxilium, Endo, and Adapt/Emergent), and a board weighted toward financial restructuring and capital-markets expertise (Bruce Bernstein, Wayne Walker, Vice-Chairman Josh Silverman of Parkfield Funding / ex-Iroquois Capital).

The business model is product sales of pharmaceutical SKUs through wholesale and pharmacy distribution, with a stated ambition to shift revenue mix toward higher-volume OTC consumer sales once switches are approved. Revenue is not publicly disclosed in the input; financial figures appear garbled in magnitude, while EBITDA is negative across all reported years, consistent with a development-stage profile. The company has funded operations through approximately $32.8M in disclosed equity financings, including a $10M offering (November 2021), two $7.5M rounds (December 2021), and a $9.6M public offering (February 2025). Securities were delisted from Nasdaq with trading suspended between April and October 2025. The partnership with IBSA (referenced in California compliance filings) and a CCPA-compliant regulatory program suggest operational and compliance maturity, but the overall capital-markets and operating profile points to a micro-cap, clinical/regulatory-stage company rather than a commercial-stage franchise.

Name

Petros Pharmaceuticals

Legal name

Petros and its subsidiaries, LLC

Website

https://petrospharma.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Petros Pharmaceuticals is a US-based, men's-health specialty pharmaceutical company pursuing an Rx-to-OTC switch strategy to convert prescription erectile dysfunction treatments into over-the-counter products distributed through wholesale and pharmacy retail channels.

Ownership category

akta.pro rank

Product category

Men's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Men's Health Pharmaceuticals
• OTC Drug Development
• Rx-to-OTC Switch
• Erectile Dysfunction Treatment
• Prescription Therapeutics

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical product sales: Petros Pharmaceuticals generates revenue through the sale of prescription and over-the-counter pharmaceuticals, primarily in the men's health category. The company is strategically shifting toward OTC drug development to expand consumer access and market reach.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Petros Pharmaceuticals identifies, develops, acquires, and commercializes novel therapeutics for men's health issues, with a strategic focus on transforming prescription pharmaceuticals into over-the-counter (OTC) treatment alternatives through Rx-to-OTC switch programs. The current product portfolio centers on erectile dysfunction treatments, including prescription and OTC-eligible pharmaceutical products and vacuum therapy devices, with the goal of expanding consumer access to medications without requiring physician prescriptions.

Product overview

Petros Pharmaceuticals operates as a single-platform pharmaceutical company focused on men's health, specifically developing an over-the-counter (OTC) drug pipeline through Rx-to-OTC switch programs. The product portfolio centers on erectile dysfunction treatments, including both pharmaceutical products and vacuum therapy devices, with a strategic emphasis on transforming prescription medications into OTC alternatives to democratize healthcare access. The company leverages technology and innovation in the self-care sector to expand consumer access to vital prescription pharmaceuticals without requiring physician visits or prescriptions.

Differentiator

Problem solved

Functional benefit

Products and services

• Erectile Dysfunction Treatment Products

Quantifiable outcome

• Over-the-counter medicines save the US healthcare system $167B annually
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• IBSAcoreStrategic or Co-development Partner · 1 January 2024IBSA is referenced in Petros Pharmaceuticals' California Compliance documentation, indicating a collaborative relationship in product development and compliance activities. The company notes that IBSA takes disciplinary and corrective actions when deemed necessary, suggesting an established working relationship in pharmaceutical operations.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Haleon: Large consumer healthcare spinoff from GSK focused on OTC switches and self-care brands across multiple therapeutic areas. Comparable because it operates the Rx-to-OTC switch model at scale and represents the type of incumbent that competes for OTC retail shelf space.
• Viatris: Global generics manufacturer that commercializes authorized and generic sildenafil and tadalafil. Comparable because it provides the low-cost generic baseline ED alternatives that any OTC Petros entry would price against.
• Perrigo Company: Specialty generic and OTC pharmaceutical manufacturer with a focus on Rx-to-OTC switches. Comparable because it operates the same store-brand and private-label OTC model Petros targets with its switch pipeline.
• Pfizer: Holds the original Viagra (sildenafil) franchise for erectile dysfunction, including the OTC-equivalent consumer efforts. Comparable because it defines the prescription ED market Petros's switch program targets and sets competitive pricing/brand benchmarks.
• Prestige Consumer Healthcare: US OTC consumer healthcare company with a portfolio of acquired and switched brands sold primarily in retail pharmacy. Comparable because its business model—acquiring Rx or existing OTC brands and scaling them through retail—is the template Petros aspires to replicate.
• Eli Lilly: Markets Cialis (tadalafil), the leading long-acting PDE5 inhibitor, including direct-to-consumer and authorized generic channels. Comparable because it is the primary branded competitor in the underlying ED molecule category Petros aims to convert to OTC.

Emerging players

• Lipocine: Small specialty pharma focused on men's health including testosterone and related therapies. Comparable because of similar company size, public listing, and men's-health-focused pipeline strategy.
• Marius Pharmaceuticals: Emerging men's health pharma commercializing specialty androgen and ED-related therapies. Comparable because of the same niche men's health focus and DTC/specialty commercial strategy.
• Aytu BioPharma: Small public specialty pharmaceutical company with branded men's health and consumer health products sold through retail and online channels. Comparable because of overlapping ED/urology therapeutic categories and small-cap public status.

Direct peers

• Endo Pharmaceuticals: Specialty pharmaceutical company with significant men's health (ED, testosterone) commercial experience including past marketing of erectile dysfunction therapies. Comparable because of overlapping men's health sales channels and ED marketing know-how.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xtwitter.com/PetrosPharma
• Facebookfacebook.com/PetrosPharmaceuticals
• LinkedInlinkedin.com/company/petros-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Petros Pharmaceuticals